1-6 of 6
Kamlesh Bisht
Close
Sort by
Journal Articles

The CD38/CD3xCD28 Trispecific Antibody (SAR442257) Potentially Represents a Novel Therapeutic Strategy for Peripheral T-Cell Lymphomas

Aurélie Dupuy, Laura Pelletier, Jerome Giustiniani, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi J. Van de Velde, Corinne Haioun, Philippe Gaulard, Nicolas Ortonne
Journal: Blood
Blood (2023) 142 (Supplement 1): 4384.
https://doi.org/10.1182/blood-2023-189088
Published: 2023
Journal Articles

A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent for the Treatment of Older Patients with Acute Myeloid Leukemia (AML)

Aintzane Zabaleta, Esperanza Martín-Sánchez, Laura Blanco, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi J. Van de Velde, Tomas Jelinek, Catia Simoes, Felipe Prosper, Jesus San-Miguel, David Martinez-Cuadron, Pau Montesinos, Bruno Paiva
Journal: Blood
Blood (2023) 142 (Supplement 1): 4178.
https://doi.org/10.1182/blood-2023-184797
Published: 2023
Journal Articles

A CD38/CD28xCD3 Trispecific T-Cell Engager (TCE) As a Potentially Active Agent in Multiple Myeloma Patients Relapsed and/or Refractory (RRMM) to Anti-CD38 Monoclonal Antibodies (mAbs)

Aintzane Zabaleta, Laura Blanco, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi J. Van de Velde, Marta Lasa, Luis-Esteban Tamariz-Amador, Paula Rodriguez Otero, Jesús San Miguel, Bruno Paiva, Esperanza Martín-Sánchez
Journal: Blood
Blood (2023) 142 (Supplement 1): 1921.
https://doi.org/10.1182/blood-2023-182150
Published: 2023
Journal Articles

Inhibition of Rho-Associated Coiled-Coil Containing Protein Kinases with Belumosudil Mesylate Shows Anti-Tumor and Immune Modulatory Properties in Models of Multiple Myeloma

Pankaj Kumar Singh, Frances N. Cervoni Curet, Cody T. Clayhold, Isere Kuiatse, Wei Tan, Marco Meloni, Monsif Bouaboula, Kamlesh Bisht, Helgi J. Van de Velde, Marielle Chiron, Angela Virone-Oddos, Robert Z. Orlowski
Journal: Blood
Blood (2023) 142 (Supplement 1): 4689.
https://doi.org/10.1182/blood-2023-188317
Published: 2023
Journal Articles

High Ex Vivo Response Rates to CD38/CD28xCD3 Trispecific T Cell Engager in Patients Relapsed after Anti-CD38 and Anti-BCMA Targeted Immunotherapies

Alana Keller, Olivia Perez De Acha, Lauren T Reiman, Zachary J Walker, David S Jayabalan, Ruben Niesvizky, Peter A Forsberg, Peter Kim, Kamlesh Bisht, Hongfang Wang, Helgi van de Velde, Daniel W. Sherbenou
Journal: Blood
Blood (2022) 140 (Supplement 1): 7097–7099.
https://doi.org/10.1182/blood-2022-169072
Published: 2022
Journal Articles

Modeling Tumor Microenvironment Interactions of Imid Sensitive and Resistant Cells in 3D Organotypic Culture Models

Aarif Ahsan, PhD, Danny Jeyaraju, Kamlesh Bisht, Patrick R. Hagner, PhD, Chad C. Bjorklund, William E Pierceall, Anjan Thakurta, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 5622.
https://doi.org/10.1182/blood-2018-99-118885
Published: 2018